The FDA continued to rewind actions tied to former leadership’s approach to disseminating guidance through restricted-circulation medical journal articles. In an update, the agency said the prior publications did not constitute official policy and formally corrected the interpretation that journal articles had replaced or functioned as agency guidance. The latest step matters for developers and compliance teams because it affects how interpretation of agency expectations is operationalized for clinical and manufacturing programs. It also highlights how internal regulatory messaging routes can change even after publication. In parallel, the Biotechnology Innovation Organization (BIO) urged withdrawal or major changes to an OMB proposal to regulate federal grants, warning that easier grant suspension and shifting from merit-based peer review toward administrative discretion could destabilize biomedical innovation funding pipelines.